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Abstract
Breast cancer remains the highest cause of worldwide cancer-related mortality. Unfortunately,
acquired therapeutic resistance occurs in the majority of cases of estrogen receptor-positive
breast cancer. An effort to discover drugs which act synergistically with Palbociclib and prevent
the development of resistance and tumor growth is essential to improving patient outcomes.
Cyclin dependent kinases (CDK) 8 and 19 are Mediator complex proteins. The Mediator
complex is an enzymatic module regulating transcription. The goal of the research is to elucidate
the mechanism by which CDK8/19 inhibitor, SNX631, prevents acquired resistance to CDK4/6
inhibitor, Palbociclib. The present study aims to elucidate the role of the senescence-associated
secretory phenotype (SASP) in Palbociclib resistance, and furthermore, to investigate if SASP is
mitigated by a novel CDK8/19 inhibitor, SNX631. It was determined that SASP was suppressed
by Palbociclib and therefore not a contributor to resistance. TGF-B, a member of SASP, was
identified as a key modulator of both tumorigenesis and cell cycle arrest in breast cancer. The
possibility that SNX631 suppresses TGF-B signaling to prevent Palbociclib resistance was
explored. Overall, it was determined that SNX631 suppresses TGF-B/Smad3 signaling
preventing changes to TGF-B signaling that occur throughout Palbociclib treatment. Lastly,
alternative mechanisms of Palbociclib resistance are present, and they should be further explored
in the context of SNX631.
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Introduction
The Insufficiency of Breast Cancer Therapy
Worldwide, breast cancer remains the highest cause of cancer-related mortality for
women. Estrogen receptor-positive (ER+)/ human epidermal growth factor receptor 2-negative
(HER2-) breast cancer makes up 40% of breast cancers (13). This breast cancer type is
commonly treated with endocrine therapy (ET), along with targeted chemotherapy. One such
target of chemotherapies are proteins involved in the progression of the cell cycle, such as
cyclin-dependent kinases (CDK), because it is through the cell cycle that all proliferation events
occur. Palbociclib (IBRANCE™) is a highly selective CDK4/6 inhibitor which is currently used
to treat ER+/HER2- breast cancers. However, 15% of patients exhibit de novo or early resistance
to Palbociclib, and 50% develop resistance within 25 months (8). Acquired resistance to
Palbociclib leads to poor patient outcomes, however, a better alternative has not yet been
developed. A potential remedy for acquired resistance to Palbociclib is combined targeted
therapy, where multiple drugs act synergistically to sustain sensitivity of the cancer to
Palbociclib. However, most chemotherapy drugs require cell cycling to be toxic, where
Palbociclib directly inhibits cell cycling, so synergistic drug combinations are hard to identify
(1).

Palbociclib-induced Senescence
CDK4 and its paralog, CDK6, form a complex with cyclin D protein which
phosphorylates retinoblastoma protein (Rb). The phosphorylation of Rb destabilizes the
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association with E2 transcription factor-1 (E2F1), and E2F1 is subsequently released. The release
of E2F1 facilitates the expression of genes that assist in the synthesis of DNA in order for the
cell to progress from the G1 phase to the S phase of the cell cycle (1). The endogenous inhibitor
of CDK4/6 is p15-INK4B, which is therefore a critical tumor suppressor. Much like p15-INK4B,
CDK4/6 inhibition by Palbociclib causes the cell cycle to be halted in the G1 phase, preventing
cell division, and slowing the growth of cancer (1).
Senescence is defined as the irreversible arrest of the cell cycle, so senescent cells do not
divide, however they are still metabolically active and secrete a variety of factors (13). Senescent
cells exhibit other phenotypic alterations such as increases of cell size, vacuolization, cell
spreading, cellular complexity, and senescence-associated β-galactosidase activity (3). The
senescence-associated secretory phenotype (SASP) is a label for the cytokine secretions that
occur by the senescent cancer cells. Secreted proteins such as interleukins (IL), tumor necrosis
factors (TNF), and transforming growth factors (TGF) exhibit paracrine activity and are
paradoxically able to modify the tissue environment in a way that promotes proliferation and
enhances tumorigenesis (13). Tumor-supporting behaviors of cytokines such as angiogenesis,
drug resistance, proliferation, and apoptosis resistance can occur in response to stimuli such as
oncogenic activity or cellular senescence (3). Reviewers found that in preclinical and clinical
breast cancer models, exposure to the IL-17 family of cytokines had pro-cancer effects for all
except IL-17E, which had mixed results (4).
Alternatively, cytokines can play a role in the suppression of cancer. Researchers found
that Th1 therapy in combination with dual tyrosine kinase inhibitor, lapatinib, sensitizes HER+
breast cancer cells to lapatinib (12). Another study showed that TGF-Β engages RAS-induced
senescence to prevent malignant transformation in human mammary epithelial cells (3).
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Consistently, cells treated with Palbociclib exhibit phenotypes of senescence within days (see
Figure S1). Since senescent cells can change the tumor microenvironment to support growth via
SASP, and breast cancer cells exhibit phenotypes of senescence in response to treatment with
Palbociclib, it was hypothesized that SASP is a tool that ER+ breast cancer uses to confer
resistance to Palbociclib.

CDK8/19 Inhibition to Prevent Resistance
Another cyclin-dependent kinase, CDK8 and its paralog, CDK19, acts as a mediator of
gene expression by regulating transcription. CDK8/19 is a member of the submodule of the
Mediator Complex, which associates numerous activator, repressor, and chromatin remodeling
proteins, with RNA polymerase II in preparation for transcription (6). CDK8/19 is involved in
the expression of genes aiding in glucose uptake, stemness, and tumor invasiveness (9). High
levels of CDK8 promote expression of c-Myc and cyclin D, proteins involved in cell division.
Additionally, CDK8 is affected by estrogen receptor signaling for transcription regulation (9).
On the other hand, CDK8/19 inhibition lowers the levels of glucose transporters and glucose
uptake to reduce cellular proliferation (8). Inhibition of CDK8/19 to treat ER+/HER2- breast
cancer is promising, as it has been shown to reduce invasiveness, metastasis, and cell
proliferation. In other cancer types, CDK8/19 inhibition can increase stem cell differentiation
(9). In organismal systems, targeting CDK8 can increase differentiation of cancerous cells and
reduce stem cell character, as well as improve NK cell cytotoxicity (9). CDK8/19 inhibition fails
to induce apoptosis in ER+ breast cancer, but it suppresses growth through synergy with other
anticancer compounds (9).
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Previous data shows that a novel CDK8/19 inhibitor, SNX631, when used in combination
with Palbociclib, prevents acquired resistance to Palbociclib by ER+ breast cancer cells in vitro
(see Figure S2). Microscopy also shows a reduction in senescent phenotypes in MCF7 treated
with the combination (see Figure S1). It is not yet understood how SNX631 works to prevent
resistance to Palbociclib in breast cancer. Since CDK8/19 is closely related to the expression of
cytokines and cell proliferation, is regulated by estrogen receptor, and has been shown to prevent
acquired resistance to Palbociclib, it was hypothesized that CDK8/19 inhibition reduces the
tumor-promoting activity of SASP to prevent the acquisition of Palbociclib resistance in ER+
breast cancer. A proposed mechanism is shown in Figure 1. Therefore, this research aims to

Figure 1. The proposed mechanism of how resistance to Palbociclib occurs. The blue-outlined box shows the
proteins involved in the progression of the G1 phase of the cell cycle. The callout bubbles are microscopic
images of MCF7 cells to demonstrate senescent morphology.

answer the question, “Does mediation of SASP by SNX631 prevent the acquisition of
Palbociclib resistance in ER+ breast cancer?”
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The Role of TGF-Β in Cancer
Transforming growth factor-beta (TGF-Β) is a super-family of crucial signaling
molecules with numerous functions, some of which stimulate tumorigenesis, some which
suppress it (2). The effect of TGF-Β changes throughout tumor progression and depends on the

Figure 2. A general timeline of changes that occur in carcinomas regarding
TGF-Β activity and responses. Source: Ben-Baruch, A. (2012). The
Inflammatory Milieu of Tumors: Cytokines and Chemokines That Affect
Tumor Growth and Metastasis. Bentham Science Publishers.

type of tumor and its microenvironment. TGF-Β production and activation tends to increase with
tumor progression. Tumor-promoting activities such as growth stimulation, enhanced migration,
and increased phenotypic instability occur (2). This trend is summarized in Figure 2.
TGF-Β molecules bind to TGF-Β receptor II (TΒRII) and recruits TΒRI. TΒRI and
TΒRII are serine kinases which phosphorylate Smad 2/3. A subsequent signal cascade involving
the Smad super-family regulates transcription (2). There are multiple signaling pathways that
TGF-Β is involved in, but the canonical Smad-signaling has primarily tumor-promoting outputs
(2) (See Figure S4 for TGF-Β signaling pathway).
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In breast carcinomas, there is a high correlation between TGF-Β1 expression and disease
progression regardless of other variables, however compromised TGF-Β pathways do not lead to
tumorigenesis alone, rather they require oncogenesis to have occurred (2). And in some cases,
overexpression of TGF-Β signaling is associated with drug resistance, and chemotherapy has
been shown to increase circulating TGF-Β (2).
In normal human mammary epithelial cells (HMEC), TGF-Β inhibits growth by
suppressing C-MYC, cyclin D, cdc25, and upregulating CDK inhibitors such has p15-INK4B (3).
TGF-Β leads to G1 arrest and inactive Rb. In response to oncogene activation in HMECs, TGFΒ induces senescence as a protective anti-tumor mechanism (3). Additionally, loss of TΒRII in
HMECs resulted in tumor progression through an overexpression of chemokines (2). This
information indicates that TGF-Β has tumor-suppressing activity in noncancerous cells but
exhibits predominantly tumor-promoting activity in cancerous cells. TGF-Β expression and
response requires cellular context and has complex chemotherapy dose responses (2).
CDK8 is a coregulator of several transcription factors such as TGF-Β/Smad and NF-κB.
CDK8 was shown to contribute to invasiveness of colon cancer through downregulation of
matrix metalloproteinase (MMP inhibitor) TIMP3 via TGFB/Smad driven expression of a
TIMP3-targeting microRNA, miR181b (6). CDK8 can interact independently with TGF-Β
signaling pathways. For example, CDK8 can phosphorylate the linker region of Smad proteins,
enhancing transcriptional activity (2).
Since TGF-Β has been shown to have tumor-supporting activity in breast cancer models,
and is affected by CDK8/19 action, I hypothesized that an increase of TGF-Β paracrine activity
contributes to Palbociclib resistance in ER+ breast cancer cells, and that CDK8/19 inhibition by
SNX631 contributes to the prevention of resistance by attenuating TGF-Β activity. This study
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aims to answer the question, “What is the role of TGF-Β in acquired resistance to Palbociclib by
ER+ breast cancer, and how does SNX631 affect it?”
The overall goal of the study was to elucidate the mechanism by which SNX631 can
prevent acquired therapeutic resistance to Palbociclib. A better understanding of the mechanism
of action of SNX631 can facilitate the use of the more effective drug combinations to treat
cancer in clinical studies, improving outcomes for breast cancer patients.

Materials and Methods
Breast cancer cell culture.
A line of MCF7 estrogen receptor-positive breast cancer cells was maintained at the
University of South Carolina for the following experiments. Cultured MCF7 was incubated at 37
°C with 5% CO2 and cultured in DMEM (Dulbecco's Modification of Eagle's Medium with 4.5
g/L glucose & L-glutamine; Corning, Corning, NY) supplemented with 10% FBS (Fetal bovine
growth serum (HyClone BGS: GE Healthcare life Sciences, HyClone Laboratories, Logan, UT)),
1% sodium pyruvate (Sigma Aldrich, St. Louis, MO), 1% penicillin/streptomycin/L-glutamate
(HyClone Laboratories, Logan, UT), and 10µg/mL insulin (Sigma Aldrich, St. Louis, MO). For
experiments, cells were seeded at a concentration of 1.5x103 cells per well on a 96-well tissue
culture dish. Outside wells contained 200 µL phosphate-buffered saline (PBS). Cells were
seeded at a concentration of 3.85x105 cells per well on a 12-well tissue culture dish. Seeded cells
were incubated for 24 h before being treated. Drugged media was replaced every 5 days unless
mentioned otherwise.
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Conditioned media production and collection.
Conditioned media was produced by culturing MCF7 in growth medium with 500 nM
Palbociclib. Four 96-well plates of cells were cultured for 3 days under 500 nM Palbociclib and
4-96 well plates of cells were cultured for 7 days, producing '3-day conditioned media' and '7day conditioned media', respectively. One hundred µL of 3- and 7- day conditioned media was
carefully removed from each well and dispensed directly into the corresponding well of a plate
with freshly seeded cells.

Conditioned media concentration pilot.
MCF7 cells were cultured in a p150 cell culture dish with 500 nM Palbociclib for 3 days
to produce '3-day conditioned media'. 13.5 mL of 3-day conditioned-media was collected and
centrifuged for 5 mins at 200 rpm. The supernatant was collected, and the pellet was discarded.
13 mL of conditioned media was diluted with fresh growth media at 10% intervals to produce
solutions of 0%-90% conditioned media. Two mL solutions of 500 nM Palbociclib in 0%-90%
conditioned media were also prepared. 200 µL of conditioned media solution was placed onto
MCF7 cells in 96-well plates as shown in Figure S4.
The plates were stained with Sulforhodamine-B (SRB) after 7 days according to the
manufacturer's instructions (see detailed methods). Absorbance of SRB solution represents cell
viability which was displayed in a line graph vs. % conditioned media. Error was represented by
the standard deviation of 6 replicates. The trend was used to determine the highest percentage of
conditioned media which did not significantly affect cell viability to use in further experiments.
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Conditioned media with drug combination.
Twelve 96-well plates of freshly seeded MCF7 cells were prepared, four with 50% 3-day
conditioned media, four with 50% 7-day conditioned media, and four with 100% fresh media.
All the 96-well plates were treated with Palbociclib or a combination of Palbociclib and SNX631
as shown in Figure S4 and described in the Detailed Methods section. One plate from each group
of media types (3-day, 7-day, fresh) was stained with SRB every 5 days, and the remaining
plates were replaced with fresh drugged media. Absorbance data for each treatment group was
displayed in bar graphs. The error was determined by the standard deviation of replicates.

TGF-Β inhibitor pilot.
MCF7 cells were seeded in two 96- well plates and treated with a range of 312.5 nM-40
µM TGF-Β receptor I (TΒRI) inhibitor (sb431542, Tocris Bioscience, Bristol, UK) (1:2dilution)
against a 0.1% DMSO vehicle. One plate was stained with SRB after 3.5 days of treatment and
the other was stained with SRB after 7 days. Average absorbance was plotted versus TBRI
inhibitor concentration to determine the highest concentration of TBRI inhibitor which did not
significantly affect cell viability.

TGF-Β inhibitor and Palbociclib combination.
MCF7 cells in a 96-well plate were treated with a range of 125-1000 nM Palbociclib. One
half of the replicates (3 wells in each row) were supplemented with 0.1% DMSO vehicle, the
other half were treated with 2.5 µM TGF-Β inhibitor. Every 5 days, one plate was stained with
SRB, and the rest received fresh drugged media. The absorbance of the wells was read and
plotted vs. Palbociclib concentration on a logarithmic scale. Error was represented by the
standard deviation of the replicates.
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Microscopy.
A representative picture of control (50% conditioned media), 500 nM Palbociclib + 50%
conditioned media, 125 nM Palbociclib + 50% conditioned media, and 500 nM Palbociclib +
500 nM SNX631 + 50% conditioned media for each media type was taken at day 5. Images were
taken using the Zeiss Axio-Imager M1 Upright Phase Contract Motorized Trinocular Microscope
in Phase 0 with an Olympus 4x objective and a Zeiss 10x objective. Images were taken again on
day 12.

Conditioned media with drug release.
MCF7 cells were seeded onto four 12-well cell culture plates 24 h prior to treatment. Two
plates received only fresh media, and two received 50% 3-day conditioned media. One well
contained 100% fresh media (negative control); 2 wells contained only 50% 3-day conditioned
media. Wells in triplicate were treated with 125 nM Palbociclib, 500 nM SNX631, or 125 nM
Palbociclib + 500 nM SNX631 (see Figure S6). Drugged media was replaced on day 5 for all the
plates. On day 10, 2 of the 4 plates had drugged media replaced with fresh drugged media and 2
of the 4 plates had drugged media replaced with fresh undrugged media. On Day 16, the cells
were stained with crystal violet according to the manufacturer's instructions. Images of the
stained 12-well plates were taken with the BIO-RAD Chemi-Doc Imager (Hercules, CA) fitted
with the White Sample Tray, set to Coomassie Blue with automatic exposure time.

RNA sequencing.
MCF7 cells were seeded in p100 tissue culture dishes at 1x106 cells per well. In replicates
of 3, the cells were treated with 0.1% DMSO, 500 nM SNX631, 500 nM Palbociclib, or 500 nM
Palbociclib + 500 nM SNX631. Ten additional dishes were treated with 500 nM Palbociclib for
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21 days, and 5 dishes were not treated (control). After 3 and 21 days of treatment, the cells were
trypsinized and collected. Total miRNA was purified with the miRNAeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. One µg of total RNA was reverse
transcribed using qScript cDNA Synthesis Kit (Quantabio, Beverly, MA). RNA quality was
evaluated on RNA-1000 chip using Bioanalyzer (Agilent, Santa Clara, CA, USA). Illumina
sequencing was performed by Medgenome (Foster City, CA). Library preparation, postprocessing of the raw data and data analysis were performed by the USC CTT COBRE
Functional genomics Core.
Gene Set Enrichment Analysis was conducted using the phenotypes DMSO, Palbociclib,
SNX631, and COMBO. The gene sets used in the analysis were “Reactome Senescence
Associated Secretory Phenotype (SASP), Wikipathways TGF-B Receptor Signaling” and
“Hallmark TGFB Signaling”. Significance was determined using False Discovery Rate <25%
and p-value <5%.

Results
Conditioned media replicates the effect of a higher Palbociclib dosage.
A range of conditioned media solutions were tested to find an appropriate percentage of
conditioned media that would not significantly affect cell viability. A treatment group with 500
nM Palbociclib and conditioned media was also tested preliminarily. Absorbance data shows that
conditioned media does not exhibit a clear trend of increasing or decreasing cell viability (Figure
3A). Additionally, the standard deviation of absorbance between the 6 replicates was unusually
large. The large variability between replicates and lack of a clear trend shows that conditioned
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media has an unpredictable effect on MCF7 cells. For cells treated with 500 nM Palbociclib and
conditioned media, an increased percentage of conditioned media was negatively correlated with
cell viability after 7 days. The standard deviation of absorbance was also slightly smaller,
indicating less variability among Palbociclib-treated MCF7. This preliminary data also suggests
that a combination of conditioned media and Palbociclib does significantly decrease cell viability
after 7 days, which is not consistent with the expectation that tumor-supporting cytokines in
conditioned media would improve cell viability. For future experiments, 50% conditioned media
was chosen because it did not exhibit a marked decrease in cell viability compared to the fresh
media control group but was also high enough to cause an effect when combined with drug.
An experiment that combined varying concentrations of Palbociclib, SNX631, and 3- and
7- day conditioned media was conducted to observe the effect of the conditioned media on
Palbociclib resistance development. The decrease in cell viability from the 3-day conditioned
media + 500 nm Palbociclib treatment group is roughly double that of the 3-day conditioned
media control after 9 days (Figure 3B). It has been shown that cells maintain an equilibrium
concentration of Palbociclib between the intracellular and extracellular space (7). This data
suggests that the conditioned media contains residual Palbociclib, and that adding 500 nM
Palbociclib to conditioned media simply increases the dosage of Palbociclib, further inhibiting
cell growth. The decrease in cell viability was not due to nutrient depletion since the 3- and 7day old 'control' media reached the same absorbance as fresh media. Among cells with
conditioned media, cell viability still increased throughout 15 days, indicating resistance to
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Palbociclib. However, it cannot be said that the conditioned media provided a 'boost' to
resistance, because viability was lower compared to cells with fresh media.

Figure 3. (A) A graph of absorbance vs. fraction conditioned media of MCF7 as the result of a 7-day cell viability assay. (B)
Absorbance for treatment groups combining conditioned media, 125 nM Palbociclib, 500 nM Palbociclib, and 500 nM SNX631 after 9
days of treatment. (C) A graph of absorbance vs. Palbociclib concentration with varying media types, with or without SNX631 after 5,
10, and 15 days of treatment. (D) Images of MCF7 after 16 days treatment with or without conditioned media and with or without drug
release at day 10, after crystal violet stain.

Additionally, there is no significant difference in cell viability between cells treated with
Palbociclib or the combination after 15 days. This suggests that conditioned media affects
untreated cells differently than treated cells. There may be a compensatory effect occurring
between the additional Palbociclib dosage and tumor-promoting cytokines in the conditioned
media, however an experiment to prove this is necessary.
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The combination of SNX631 and Palbociclib was able to prevent Palbociclib resistance for all
media types.
In both 3-day and 7-day conditioned media treatment groups, the absorbance of cells
treated with both 500 nM Palbociclib and 500 nM SNX631 remained low after 15 days,
indicating that the combinatory inhibition of CDK4/6 and CDK8/19 prevented the development
of resistance to Palbociclib (Figure 3). This has been shown to occur in cells with fresh media as
well (See Figure S1). Since this trend is observed regardless of media type, the ability of
SNX631 to prevent resistance is not dependent on cytokine secretions by senescent cells.
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RNA sequencing shows that the expression of genes involved in SASP is low in Palbociclib vs.
Control MCF7 after 3 and 21 days of treatment.
Sequencing of mRNA transcripts from MCF7 cells treated with Palbociclib or DMSO for
3 and 21 days was conducted to compare how gene expression changes over time in response to
Palbociclib. Gene Set Enrichment Analysis (GSEA) was used to analyze a gene set for the
senescence-associated secretory phenotype. GSEA shows that the genes were significantly
under-expressed in Palbociclib vs. DMSO after 3 and 21 days of treatment (Figure 4). In fact, the
enrichment score (ES) of Palbociclib vs. Control after 21 days (ES=-0.55) was lower than
Palbociclib vs. DMSO (ES=-0.47) after 3 days. The combination of SNX631 and Palbociclib
was shown to slightly further decrease expression of SASP genes after 3 days vs. Palbociclib
alone (ES=-0.28), however this result was not significant.

Figure 4.GSEA Enrichment Score Plots and Heat maps of the 25 most affected genes in the SASP gene set for MCF7 comparing (A) 3
days Palbociclib vs. control. (B) 3-day combination vs 3-day Palbociclib and (C) 21-day Palbociclib vs. Control.
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A combination of CDK4/6 inhibition and TΒRI inhibition produced a slight increase in MCF7
cell viability.
A TΒRI inhibitor was combined with Palbociclib to determine if TΒRI inhibition by
SNX631 was an avenue for prevention of Palbociclib resistance. Alone, TBRI inhibition did not
have a significant effect on MCF7 cell viability below 5 µM (Figure 5A). 2.5 µM concentration
of TBRI inhibitor was chosen for future experiments. TΒRI inhibition in combination with
Palbociclib improved viability of MCF7 cells over 20 days compared to those treated with
Palbociclib alone (Figure 5B), which conflicts with the expectation that the combination would
decrease viability vs. Palbociclib alone. There is also a lack of sensitivity to Palbociclib
demonstrated by continued cell growth over 10 days, which suggests that resistance occurs with
or without TΒRI activity. This does not replicate the synergistic negative effect exhibited by
SNX631 and is not consistent with the hypothesis that TBRI was the avenue through which
SNX631 prevents resistance.

Figure 5. (A) Absorbance vs TΒRI inhibitor concentration after 3.5 and 7 days of treatment. Alone, TΒRI inhibitor does not have a significant
effect on cell viability below 5 µM. (B) Absorbance vs Palbociclib concentration with and without TΒRI inhibitor after 5 and 10 days of
treatment.
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Among genes that are upregulated in response to TGF-Β1, Palbociclib-treated MCF7 saw an
alteration of expression over time.
GSEA of a set of genes that are expected to be upregulated in response to TGF-Β1
stimulation shows that those genes are significantly upregulated in Palbociclib-treated MCF7 vs.
DMSO after 3 days (ES=0.5). However, after 21 days of Palbociclib treatment, the same genes
are significantly downregulated (ES=-0.29) (Figure 6). This is not consistent with the fact that
TGFB1 transcripts are upregulated vs control cells at both 3 (fc= 1.36) and 21 days (fc=1.14) of
Palbociclib treatment (Figure 7), suggesting that sensitivity to TGF-B1 is reduced as resistance
develops.

Figure 6. GSEA enrichment plots and heat maps comparing expression of a set of genes involved in TGF-Β1 signaling
between treatment groups (A) 3-day Palbociclib vs. DMSO. (B) 3-day Palbociclib + SNX631 vs. Palbociclib (C) 21-day
Palbociclib vs. Control.

21

Figure 7. Box and Whisker plots showing counts per million of mRNA transcripts of TGFB, TGF-Β receptor genes,
and Smad3 for each treatment group after 3 days of treatment.
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The combination of Palbociclib and SNX631 causes significant downregulation of TGF-Β
receptor signaling vs Palbociclib alone.
GSEA shows that the combination treatment significantly downregulates TGF-Β1
associated genes compared to Palbociclib alone after 3 days (ES=-0.47). The 3-day combination
treatment showed the lowest number of TGFB1 transcripts (2.5 cpm), compared to 3-day
Palbociclib (7.9 cpm) 21-day Palbociclib (15.1 cpm) and DMSO (5.3 cpm). This result suggests
that SNX631 suppresses TGF-B1 to prevent the development of resistance to Palbociclib.
Among genes associated with TΒRI signaling, the combination significantly
downregulated these genes vs. Palbociclib alone after 3 days. Those genes were not significantly
enriched vs. DMSO. This suggests that the combination treatment suppresses the changes in
TΒRI signaling that occur with Palbociclib treatment.

Figure 8. GSEA enrichment plots and heat maps for a set of genes that is involved in TGF-Β receptor signaling. (A)
3-day Palbociclib vs. DMSO. (B) 3-day Palbociclib + SNX631 vs. Palbociclib (C) 21-day Palbociclib vs. Control.
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Other Palbociclib resistance mechanisms are prevalent according to RNA sequencing.
There are various mechanisms of resistance to Palbociclib established by the literature.
For example, the activity of CDK6 increases and facilitates phosphorylation of Rb in absence of
CDK4 activity. RNA sequencing shows that transcripts of CDK6 are significantly upregulated in
Palbociclib treated cells and less so in combination-treated cells. Additionally, CDK2/cyclin E
phosphorylates Rb after the initial phosphorylation by CDK4/cyclin D. Palbociclib resistance can
be conferred by an increase in CDK2/cyclin E activity, where Rb can be phosphorylated without
CDK4/6. RNA sequencing shows that CDK2 expression increases after 21 days of Palbociclib
treatment but remains low for combination-treated cells (Table I). Current research shows that
combined CDK2 and CDK4/6 inhibition prevents resistance to Palbociclib in breast cancer cells
by enhancing C-MYC modulated senescence (10). C-MYC expression is high in combinationtreated cells, suggesting that C-MYC modulated senescence is maintained (Table I).
Smad3 suppression has been cited as a possible mechanism for Palbociclib resistance
(11). Inhibition of Smad3 activity leads to loss of cell cycle arrest in cancer by overexpression of
cyclin D (11). Consistent with this hypothesis, the gene encoding Smad3 is significantly
downregulated in the combination vs. Palbociclib after 3 days. Also, CCNDI expression
(encoding cyclin D) is high in all treatment groups (Table I). Together, CDK8/19 inhibition may
prevent resistance by suppressing the TGF-B/Smad signaling cascade.
P53 is tumor suppressor protein involved in the regulation of the cell cycle. P53 loss-offunction mutations have been associated with the resistance of many chemotherapies by various
cancers. RNA sequencing shows a significant increase in expression of TP53 (p53 encodinggene) in combination-treated MCF7 cells, which may contribute to sustained cell cycle arrest
(Table I).
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Fold-change vs. Control
GENE

CDK2
CCNA2
CDK6
CCND1
TP53
CMYC
SMAD2
SMAD3

PROTEIN
PRODUCT

CDK2
cyclin A
CDK6
cyclin D1
p53
c-myc
Smad2
Smad3

Treatment Group
3-day
Palbociclib
0.53
0.29
2.64
1.63
0.72
0.89
0.60
2.35

21-day Palbociclib
1.14
0.72
2.09
1.36
0.37
0.57
N/A
1.45

3-day SNX631
0.78
0.86
0.72
1.07
1.12
1.31
0.67
0.92

3-day Pal +SNX
0.45
0.31
1.12
1.36
0.86
1.81
0.69
1.28

Table I. Shows the fold-change relative to DMSO control in counts per million of gene transcripts
associated with drug resistance or cell cycle arrest for each treatment group analyzed with mRNA sequencing.

Discussion
The eventual progression of ER+ breast cancer, despite treatment with endocrine therapy
and CDK4/6 inhibitors, prompts the investigation of the mechanisms of acquired drug resistance.
There are many mechanisms of Palbociclib resistance that have been established by the
literature. ER+ breast cancer exhibits phenotypes of senescence after exposure to Palbociclib,
and senescence-associated secretory phenotypes that result from senescence can become tumorsupporting and promote drug resistance. However, combination therapy with CDK8/19 inhibitor
SNX631 reduces senescence phenotypes, so it was hypothesized that SNX631 was also
preventing SASP-induced resistance to Palbociclib.
This idea inspired experimentation with media conditioned with secretions from
Palbociclib-treated cells. Cell viability assays show that conditioned media had a negative effect
on cell growth over 20 days compared to fresh growth media. Because literature demonstrates
that residual Palbociclib remains in the media, it cannot be effectively discerned whether the
decrease in cell viability was due to tumor-suppressing cytokine secretions or due to an
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unintentional higher dosage of Palbociclib. A further study with conditioned media where
Palbociclib was first removed would be beneficial to separating the effects of these confounding
variables. Additionally, the pilot experiment where varying concentrations of conditioned media
were used, and the crystal violet assay provide evidence that suggests that conditioned media has
a variable effect on cell growth that cannot be accurately predicted, especially in the presence of
Palbociclib.
GSEA analysis showed that genes associated with SASP were significantly
downregulated in Palbociclib-treated MCF7 after 3-days and 21-days. This suggests that SASP is
not a driver of resistance in MCF7, as previously hypothesized. This could be possibly explained
by the reversal of senescence in the cells as they reenter the cell cycle. A further study could
investigate the SASP on a protein level, with a proteome analysis of conditioned media, to
determine which cytokines are being secreted from the cells.
GSEA regarding the combination treatment was not significant, making it difficult to
discern the effect of SNX631 on cytokine secretions. However, cell viability assays show that the
combination treatment prohibits cell growth regardless of the addition of conditioned media,
suggesting that the success of SNX631 should not be fully contributed to SASP attenuation.
Since TGF-Β is a key signaling molecule, has been associated with tumorigenesis, and
has been shown to be affected by CDK8/19, it was hypothesized that TGF-Β signaling was an
avenue through which SNX631 inhibition might prevent acquired Palbociclib resistance.
However, cell viability assays showed that a combination of Palbociclib and TΒRI
inhibitor did not inhibit cell growth over 20 days, but rather improved it. This does not replicate
the effect of SNX631 in combination with Palbociclib, and therefore does not support the
hypothesis. GSEA analysis shows that TGF-Β signaling is heavily upregulated in Palbociclib-
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treated cells, coinciding with an increase in genes encoding TGF-Β1. The combination decreases
the signaling closer to levels of untreated cells. The data may indicate a lower reliance upon
TGF-Β signaling after 21 days of Palbociclib treatment, where the combination treatment
maintains TGF-Β sensitivity and activity. Alternatively, combination treatment could cause a
switch of predominant TGF- Β isoform from type 1 to type 2, which serve different functions.
Overall, the CDK8/19 inhibition leads to abrogation of TGF-B-induced Palbociclib resistance.
TGF-Β gene transcripts experience significant translational regulation, so conclusions made
based on RNA sequencing must be confirmed at a protein level.
According to RNA sequencing, Palbociclib-treated cells exhibit published mechanisms of
resistance such as suppression of Smad3, overexpression of cyclin D, CDK6, CDK2, and
suppression of p53. There is some evidence that SNX631 counteracts these mechanisms, giving
cause to further examine these resistance mechanisms in the context of SNX631.

Conclusions
This study intended to explore SASP as a mechanism of Palbociclib resistance and
examine the ability of SNX631 to attenuate SASP. The conditioned media experiment was not a
successful determinant of the presence of tumor-supporting cytokine secretions. The study found
that the combination treatment suspended proliferation of the breast cancer cells even in the
presence of conditioned media, which suggests that SNX631 works regardless of cytokine
secretions. GSEA also suggests that SASP is suppressed in Palbociclib-treated cells.
Research shows that the role of TGF-Β in tumorigenesis and cell cycle arrest is complex.
It was hypothesized that TGF-Β is suppressed by CDK8/19 inhibition. The study found that in
this context, an increase of TGF-Β signaling occurs with Palbociclib treatment, but
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paradoxically, inhibition of TBRI is associated with an increase in cell growth. Based on RNA
sequencing data, SNX631 was shown to suppress TGF-Β/Smad signaling in combination with
Palbociclib, which supports the hypothesis that TGF-B inhibition is key to the prevention of
Palbociclib resistance. Due to these contradictory results, the role of TGF-Β signaling on
Palbociclib resistance is complex, and the effect of SNX631 on TGF-B has yet to be fully
understood.
Overall, this study indicates that further scientific investigation should be directed
towards understanding how SNX631 affects the TGF-B/Smad axis, along with previously
suggested mechanisms of resistance of Palbociclib. Knowledge regarding the effects of
combinatory CDK4/6 and CDK8/19 inhibition is essential for improving treatment of estrogen
receptor-positive breast cancer.
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Supplementary Materials
Supplementary Figures

Figure S1. Microscopic images of MCF7 cells after 10 days of treatment with either 500 nM Palbociclib or 500 nM
Palbociclib + 1 µM SNX631 or equivalent DMSO vehicle control show that senescent morphology occurs in
Palbociclib-treated cells but occurs less strongly in combination-treated cells.
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Figure
S2. (A)Crystal violet staining of flasks with MCF7 cells treated with Palbociclib for 33 days, SNX631 for 10
.
days, or a combination for 33 days. (B) A preliminary cell viability assay shows the effects of a combination of
Palbociclib and SNX631 on MCF7 cell viability after 20 days. Palbociclib and SNX631 combination treatment
conditions (red lines) show no cell growth over 20 days.

Figure S3. A diagram of the experimental setup of the 96-well plates for the Conditioned media pilot experiment. One
plate included 500 nM Palbociclib with a dilution of conditioned media.
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Figure S2. A simplified pathway of TGF-Β/Smad signaling leading to transcription regulation. Source:
wikipathways

Figure S5. A diagram of the experimental setup of the 96-well plates for the conditioned media and drug
combination experiment.
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Figure S6. A timeline of plating, treating, and staining to produce conditioned media and conduct the conditioned
media experiment.

Figure S7. A diagram of the experimental setup of the conditioned media with drug release
experiment. C is ‘control’, a treatment group with 100% fresh media, C w/ CM is a treatment
group with 50% conditioned media but without drugs.
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Detailed Methods
Serial Dilution of Palbociclib and SNX631.
24 h after seeding, media was removed from the wells of the 96-well culture dish. 100 µL
fresh media was loaded into each well. Solutions of 8.5 mL 8 µM Palbociclib and 13 mL 4 µM
Palbociclib were prepared. Thirty-two mL of 2 µM SNX631 was prepared. Four concentrations
of Palbociclib were tested: 1000 nM, 500 nM, 250 nM, and 125 nM. To prepare the serial
dilution, 100 µL of 4 µM Palbociclib stock was placed into the third row of the plate with a
multichannel pipettor. The 4 µM stock was carried to each subsequent row, diluting the
concentration by 0.5. This was repeated with the 8 µM Palbociclib stock for rows 8-11. One
hundred µL of 2 µM SNX631 stock was added to rows 8-11 for the 'combination’ treatment. 100
µL media was removed from the 'combination' wells, and 100 µL 100% conditioned media was
added to all the wells, producing a 50% conditioned media solution for the entire plate.

Sulforhodamine-B staining protocol.
MCF7 cells were fixed with 10% ice-cold trichloroacetic acid in dH2O and incubated at 4
°C for 10 minutes. The plates were rinsed with water. The cells were then stained with 0.4%
sulforhodamine-B in 1% acetic acid and incubated at room temperature for 10 minutes. After
rinsing with 1% acetic acid in dH2O, the plates were incubated at 37 °C (no CO2) overnight. The
SRB crystals were solubilized in a 20 µM TRIS base and rocked for 1-2 h. Absorbance of the
crystals in each well was measured with a BIO-RAD iMark™ Microplate Reader (Hercules, CA)
at 570 nm excitation wavelength.
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Crystal Violet staining protocol.
Media was aspirated off the cells. They were washed gently with non-sterile PBS. The cells were
fixed with 1-2 mL 80% methanol, 20% acetic acid solution and incubated for 10 minutes at room
temperature. The cells were gently washed with room temperature non-sterile (PBS). The cells
were then stained with 1-2 mL 0.5% Crystal Violet in 10% methanol and incubated at room
temperature for 5 minutes. The stain was washed out with dH2O and dried on the bench
overnight.
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